-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $459

Benzinga·10/08/2026 14:45:02
Diffusion vocale
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $450 to $459.